U
UroGen Pharma Ltd. (URGN)
NGM – Real vaqt narxi. Valyuta: USD
29.80
-1.53 (-4.88%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
29.80
-1.53 (-4.88%)
Yopilishda: May 12, 2026, 4:00 PM EDT
UroGen Pharma Ltd., biotexnologiya kompaniyasi, urotelial va ixtisoslashgan saraton turlari uchun yechimlarni ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya RTGel'ni taklif etadi, bu yangi patentlangan polimerli biomutahassis, termal gelatsiyali gidrogel texnologiyasi; mitomitsin, siydik pufagi o'simtasini trans-uretral rezektsiyasidan keyin past darajadagi NMIBCni davolash uchun yordamchi kimyoterapiya sifatida qo'llaniladigan jenerik dori; Zusduri, mushak-invaziv bo'lmagan siydik pufagi saratonini (NMIBC) davolash uchun mitomitsinning sekin chiqariladigan shakli; va Jelmyto buyrak-chaft (pyelocalyceal) eritmalari uchun. Kompaniyaning etakchi mahsulot nomzodlari orasida UGN-103 bor, u intravezikal eritma uchun 3-bosqichli klinik sinovda; va UGN-104, buyrak-chaft eritmasi uchun 3-bosqichli klinik sinovda bo'lib, past darajadagi yuqori trak urotelial saratoni va past darajadagi oraliq xavfli NMIBCni o'z ichiga olgan mushak-invaziv bo'lmagan urotelial saratonning bir necha shakllarini davolash uchun mo'ljallangan. Kompaniya, shuningdek, yuqori darajadagi NMIBCni davolash uchun 1-bosqichli klinik sinovda bo'lgan UGN-301, UGN-301+UGN 201 va UGN-301+gemtsitabinni ishlab chiqmoqda. Kompaniya Agenus Inc. bilan siydik yo'llari saratonini intravezikal yuborish orqali davolash uchun Agenus mahsulotlarini ishlab chiqish, ishlab chiqarish, ishlatish, sotish, import qilish va tijoratlashtirish bo'yicha litsenziya shartnomasini; va medac Gesellschaft für klinische Spezialpräparate m.b.H. bilan UGN-103 va UGN-104ni ishlab chiqish bo'yicha litsenziya va ta'minot shartnomasini imzolagan. UroGen Pharma Ltd. 2004 yilda tashkil etilgan va shtab-kvartirasi Prinston, Nyu-Jersi shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Marina Konorty Ph.D. | Executive Vice President of Research & Development and Technical Operations |
| Dr. Mark P. Schoenberg M.D. | Chief Medical Officer |
| Mr. Christopher Degnan CPA | Chief Financial Officer |
| Mr. James Ottinger R.ph. | Executive Vice President of Regulatory Affairs & Quality |
| Mr. Jason Drew Smith J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Mr. Michael J. Louie M.D., M.P.H., M.Sc. | Chief Development Officer |
| Mr. Timothy Simon | Senior Vice President of Business Development & Portfolio Strategy |
| Mr. Vincent I. Perrone | Senior Director of Investor Relations |
| Ms. Alison Hardgrove | Senior Vice President of Human Resources |
| Ms. Elizabeth A. Barrett | President, CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 8-K | urgn20260504_8k.htm |
| 2026-05-06 | 10-Q | urgn20260331_10q.htm |
| 2026-04-30 | DEF 14A | urgn20260312_def14a.htm |
| 2026-04-17 | PRE 14A | urgn20260312_pre14a.htm |
| 2026-03-02 | 8-K | urgn20260226_8k.htm |
| 2025-11-06 | S-3ASR | d892603ds3asr.htm |
| 2025-08-27 | 8-K | urgn20250826_8k.htm |
| 2025-08-07 | 10-Q | urgn20250630_10q.htm |
| 2025-07-16 | ARS | uroars.pdf |
| 2025-07-15 | DEF 14A | urgn20250605_def14a.htm |